Low disease activity in patients with lupus nephritis linked with reduced economic burden

Patients with lupus nephritis (LN) who achieved low disease activity were linked with reduced economic burden to healthcare payers, according to data presented at the European Alliance of Associations for Rheumatology (EULAR) 2021 Congress.

Average monthly medical costs and total monthly costs were reduced by $2254 and $3028, respectively, in patients with low disease activity compared to during periods of active disease.

In this retrospective observational analysis including 21,251 patients with LN, 51.3% had evidence of low disease, with a mean duration of 27.5 months. During periods of low disease activity and during periods of active disease, mean monthly medical costs were $2523 and $4777, respectively.

The mean month costs associated with end-stage renal disease were $18,084 and $3760 for medical and pharmacy, respectively.

Reference
Mina-Osorio P, et al. Real-world economic implications of achieving low disease activity in lupus nephritis. Presented at: European Alliance of Associations for Rheumatology (EULAR) 2021 Congress.